The ULK1-FBXW5-SEC23B Nexus Controls Autophagy
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Role of FBXW5-Loss in Centrosome Abnormalities and Cell Physiology
Role of FBXW5-loss in Centrosome Abnormalities and Cell Physiology Dissertation der Mathematisch-Naturwissenschaftlichen Fakultät der Eberhard Karls Universität Tübingen zur Erlangung des Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) vorgelegt von Tim Scholta aus Spremberg Tübingen 2021 Gedruckt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Eberhard Karls Universität Tübingen. Tag der mündlichen Qualifikation: 12.07.2021 Dekan: Prof. Dr. Thilo Stehle 1. Berichterstatter: Prof. Dr. Nisar Malek 2. Berichterstatter: Prof. Dr. Alfred Nordheim Content 1 Abbreviations ................................................................................................................................ 6 2 Abstract ......................................................................................................................................... 8 3 Zusammenfassung ....................................................................................................................... 9 4 Introduction ................................................................................................................................. 10 4.1 The importance of centrosomes in maintaining genomic stability ....................................... 10 4.2 Centrosome amplification – Cause or consequences of tumor formation? ......................... 12 4.3 Centrosome and Centrosome cycle ..................................................................................... 14 4.3.1 Disengagement/licensing of the centrosome -
A Case Report of Congenital Erythropoietic Anemia II in China with a Novel Mutation
Annals of Hematology https://doi.org/10.1007/s00277-019-03612-2 LETTER TO THE EDITOR A case report of congenital erythropoietic anemia II in China with a novel mutation Hong Zhang1 & Wuqing Wan1 & Xiaoyan Liu1 & Chuan Wen1 & Ying Liu1 & Senlin Luo1 & Xiao Sun1 & Shizhe Liu1 Received: 19 December 2018 /Accepted: 4 January 2019 # The Author(s) 2019 Dear Editor, 53.9 μmol/L (normal, 0–21), of which 42.7 μmol/L was Congenital erythropoietic anemias (CDAs) are a indirect (normal, 0–19). G6PD deficiency was not found. group of rare inherited diseases [1]. So far, the CDAs Red blood cell folate and hemoglobin electrophoresis are mainly divided into four types (type I to type IV), gave results within normal limits. Serum vitamin B12 and the CDA type II is the most common type. It is was 736 pmol/L (normal, 133–675). Serum iron, ferritin, caused by a mutation in the SEC23B gene. To date, 67 and transferrin were all within normal limits. Erythrocyte causative mutations in the SEC23B gene have been de- osmotic fragility test was normal. Acidified glycerol he- scribed [2–5] (the complete mutational spectrum of molysis test and Coombs test were negative. Light micro- SEC23B isshowninTable1). scope observation of a bone marrow smear revealed hy- We report a patient with typical clinical manifesta- perplasia and binucleated late erythroblasts (Fig. 1a). tions and laboratory findings, a 6-year-old girl who Genetic testing of the proband, her little brother, and hadsufferedjaundiceattheageof6monthswithlow her parents performed at Shanghai Xin Peijing Medical hemoglobin levels at 80 g/L. -
Murine SEC24D Can Substitute Functionally for SEC24C in Vivo
bioRxiv preprint doi: https://doi.org/10.1101/284398; this version posted March 22, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Functional Overlap Between Mouse SEC24C and SEC24D Murine SEC24D Can Substitute Functionally for SEC24C in vivo Elizabeth J. Adams1,2, Rami Khoriaty2,3, Anna Kiseleva1, Audrey C. A. Cleuren1,7, Kärt Tomberg1,4, Martijn A. van der Ent3, Peter Gergics4, K. Sue O’Shea5, Thomas L. Saunders3, David Ginsburg1-4,6,7 1From the Life Sciences Institute, 2Program in Cellular and Molecular Biology, 3Department of Internal Medicine, 4Departement of Human Genetics, 5Department of Cell and Developmental Biology, 6Department of Pediatrics and the 7Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109 ABSTRACT The COPII component SEC24 mediates the recruitment of transmembrane cargoes or cargo adaptors into newly forming COPII vesicles on the ER membrane. Mammalian genomes encode four Sec24 paralogs (Sec24a-d), with two subfamilies based on sequence homology (SEC24A/B and C/D), though little is known about their comparative functions and cargo-specificities. Complete deficiency for Sec24d results in very early embryonic lethality in mice (before the 8 cell stage), with later embryonic lethality (E 7.5) observed in Sec24c null mice. To test the potential overlap in function between SEC24C/D, we employed dual recombinase mediated cassette exchange to generate a Sec24cc-d allele, in which the C-terminal 90% of SEC24C has been replaced by SEC24D coding sequence. In contrast to the embryonic lethality at E7.5 of SEC24C-deficiency, Sec24cc-d/c-d pups survive to term, though dying shortly after birth. -
Genetic Drivers of Pancreatic Islet Function
| INVESTIGATION Genetic Drivers of Pancreatic Islet Function Mark P. Keller,*,1 Daniel M. Gatti,†,1 Kathryn L. Schueler,* Mary E. Rabaglia,* Donnie S. Stapleton,* Petr Simecek,† Matthew Vincent,† Sadie Allen,‡ Aimee Teo Broman,§ Rhonda Bacher,§ Christina Kendziorski,§ Karl W. Broman,§ Brian S. Yandell,** Gary A. Churchill,†,2 and Alan D. Attie*,2 *Department of Biochemistry, §Department of Biostatistics and Medical Informatics, and **Department of Horticulture, University of Wisconsin–Madison, Wisconsin 53706-1544, †The Jackson Laboratory, Bar Harbor, Maine 06409, and ‡Maine School of Science and Mathematics, Limestone, Maine 06409, ORCID IDs: 0000-0002-7405-5552 (M.P.K.); 0000-0002-4914-6671 (K.W.B.); 0000-0001-9190-9284 (G.A.C.); 0000-0002-0568-2261 (A.D.A.) ABSTRACT The majority of gene loci that have been associated with type 2 diabetes play a role in pancreatic islet function. To evaluate the role of islet gene expression in the etiology of diabetes, we sensitized a genetically diverse mouse population with a Western diet high in fat (45% kcal) and sucrose (34%) and carried out genome-wide association mapping of diabetes-related phenotypes. We quantified mRNA abundance in the islets and identified 18,820 expression QTL. We applied mediation analysis to identify candidate causal driver genes at loci that affect the abundance of numerous transcripts. These include two genes previously associated with monogenic diabetes (PDX1 and HNF4A), as well as three genes with nominal association with diabetes-related traits in humans (FAM83E, IL6ST, and SAT2). We grouped transcripts into gene modules and mapped regulatory loci for modules enriched with transcripts specific for a-cells, and another specific for d-cells. -
Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories
Supplementary Table 1: Association of Gene Ontology Categories with Decay Rate for HepG2 Experiments These tables show details for all Gene Ontology categories. Inferences for manual classification scheme shown at the bottom. Those categories used in Figure 1A are highlighted in bold. Standard Deviations are shown in parentheses. P-values less than 1E-20 are indicated with a "0". Rate r (hour^-1) Half-life < 2hr. Decay % GO Number Category Name Probe Sets Group Non-Group Distribution p-value In-Group Non-Group Representation p-value GO:0006350 transcription 1523 0.221 (0.009) 0.127 (0.002) FASTER 0 13.1 (0.4) 4.5 (0.1) OVER 0 GO:0006351 transcription, DNA-dependent 1498 0.220 (0.009) 0.127 (0.002) FASTER 0 13.0 (0.4) 4.5 (0.1) OVER 0 GO:0006355 regulation of transcription, DNA-dependent 1163 0.230 (0.011) 0.128 (0.002) FASTER 5.00E-21 14.2 (0.5) 4.6 (0.1) OVER 0 GO:0006366 transcription from Pol II promoter 845 0.225 (0.012) 0.130 (0.002) FASTER 1.88E-14 13.0 (0.5) 4.8 (0.1) OVER 0 GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism3004 0.173 (0.006) 0.127 (0.002) FASTER 1.28E-12 8.4 (0.2) 4.5 (0.1) OVER 0 GO:0006357 regulation of transcription from Pol II promoter 487 0.231 (0.016) 0.132 (0.002) FASTER 6.05E-10 13.5 (0.6) 4.9 (0.1) OVER 0 GO:0008283 cell proliferation 625 0.189 (0.014) 0.132 (0.002) FASTER 1.95E-05 10.1 (0.6) 5.0 (0.1) OVER 1.50E-20 GO:0006513 monoubiquitination 36 0.305 (0.049) 0.134 (0.002) FASTER 2.69E-04 25.4 (4.4) 5.1 (0.1) OVER 2.04E-06 GO:0007050 cell cycle arrest 57 0.311 (0.054) 0.133 (0.002) -
Congenital Dyserythropoietic Anemia Type II
Punzo et al. Orphanet Journal of Rare Diseases 2011, 6:89 http://www.ojrd.com/content/6/1/89 RESEARCH Open Access Congenital Dyserythropoietic Anemia Type II: molecular analysis and expression of the SEC23B Gene Francesca Punzo1,2, Aida M Bertoli-Avella1, Saverio Scianguetta2, Fulvio Della Ragione3, Maddalena Casale2, Luisa Ronzoni4, Maria D Cappellini4, Gianluca Forni5, Ben A Oostra1 and Silverio Perrotta2* Abstract Background: Congenital dyserythropoietic anemia type II (CDAII), the most common form of CDA, is an autosomal recessive condition. CDAII diagnosis is based on invasive, expensive, and time consuming tests that are available only in specialized laboratories. The recent identification of SEC23B mutations as the cause of CDAII opens new possibilities for the molecular diagnosis of the disease. The aim of this study was to characterize molecular genomic SEC23B defects in 16 unrelated patients affected by CDAII and correlate the identified genetic alterations with SEC23B transcript and protein levels in erythroid precursors. Methods: SEC23B was sequenced in 16 patients, their relatives and 100 control participants. SEC23B transcript level were studied by quantitative PCR (qPCR) in peripheral erythroid precursors and lymphocytes from the patients and healthy control participants. Sec23B protein content was analyzed by immunoblotting in samples of erythroblast cells from CDAII patients and healthy controls. Results: All of the investigated cases carried SEC23B mutations on both alleles, with the exception of two patients in which a single heterozygous mutation was found. We identified 15 different SEC23B mutations, of which four represent novel mutations: p.Gln214Stop, p.Thr485Ala, p.Val637Gly, and p.Ser727Phe. The CDAII patients exhibited a 40-60% decrease of SEC23B mRNA levels in erythroid precursors when compared with the corresponding cell type from healthy participants. -
Consequences of Mutations in the Genes of the ER Export Machinery COPII in Vertebrates
Biomedical Sciences Publications Biomedical Sciences 1-22-2020 Consequences of mutations in the genes of the ER export machinery COPII in vertebrates Chung-Ling Lu Iowa State University, [email protected] Jinoh Kim Iowa State University, [email protected] Follow this and additional works at: https://lib.dr.iastate.edu/bms_pubs Part of the Cellular and Molecular Physiology Commons, Molecular Biology Commons, and the Molecular Genetics Commons The complete bibliographic information for this item can be found at https://lib.dr.iastate.edu/ bms_pubs/81. For information on how to cite this item, please visit http://lib.dr.iastate.edu/ howtocite.html. This Article is brought to you for free and open access by the Biomedical Sciences at Iowa State University Digital Repository. It has been accepted for inclusion in Biomedical Sciences Publications by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Consequences of mutations in the genes of the ER export machinery COPII in vertebrates Abstract Coat protein complex II (COPII) plays an essential role in the export of cargo molecules such as secretory proteins, membrane proteins, and lipids from the endoplasmic reticulum (ER). In yeast, the COPII machinery is critical for cell viability as most COPII knockout mutants fail to survive. In mice and fish, homozygous knockout mutants of most COPII genes are embryonic lethal, reflecting the essentiality of the COPII machinery in the early stages of vertebrate development. In humans, COPII mutations, which are often hypomorphic, cause diseases having distinct clinical features. This is interesting as the fundamental cellular defect of these diseases, that is, failure of ER export, is similar. -
Mutations in the Coat Complex II Component SEC23B
Yang et al. Cell Death and Disease (2020) 11:157 https://doi.org/10.1038/s41419-020-2358-7 Cell Death & Disease ARTICLE Open Access Mutations in the coat complex II component SEC23B promote colorectal cancer metastasis Chunyuan Yang1,NanChen2,XiangLi1, Dan Lu3,ZhiyuanHou3,YuhuaLi3,YanJin3,JinGu2 and Yuxin Yin1,3 Abstract Metastasis is the leading cause of death for colorectal cancer (CRC). However, the protein transport process involved in CRC metastasis remains unclear. In this report, we use whole-exome sequencing and bioinformatics analysis to identify somatic mutations in CRC samples and found mutations of the protein transport gene Sec23 homolog B (SEC23B)in patients with metachronous liver metastasis. We show that deletion of SEC23B suppresses the membrane localization of adhesion proteins and augments cell mobility. SEC23B mutations either cause a premature stop (C649T) or impair its protein transport activity (C1467G and T488C + G791A + G2153A). Furthermore, SEC23B mutations inhibit the transport of epithelial cell adhesion molecule (EPCAM) and CD9 molecule, thereby attenuating cell adhesion and promoting invasiveness both in vitro and in vivo. Taken together, these data demonstrate the important impact of SEC23B mutations on metastasis, and we propose that SEC23B is a potential suppressor of CRC metastasis. Introduction pathway consists of a set of organelles and cargo-bearing Colorectal cancer (CRC) is one of the most prevalent vesicles10,11. The first step of this pathway is the transport 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; cancers worldwide. According to the World Health of protein from endoplasmic reticulum (ER) to Golgi Organization (WHO), nearly 1.1 million individuals are apparatus, mediated by the coat protein II (COPII) com- diagnosed with CRC each year1. -
PRODUCT SPECIFICATION Product Datasheet
Product Datasheet QPrEST PRODUCT SPECIFICATION Product Name QPrEST FBXW5 Mass Spectrometry Protein Standard Product Number QPrEST33470 Protein Name F-box/WD repeat-containing protein 5 Uniprot ID Q969U6 Gene FBXW5 Product Description Stable isotope-labeled standard for absolute protein quantification of F-box/WD repeat- containing protein 5. Lys (13C and 15N) and Arg (13C and 15N) metabolically labeled recombinant human protein fragment. Application Absolute protein quantification using mass spectrometry Sequence (excluding PDNRYLYVNSRAWPNGAVVADPMQPPPIAEEIDLLVFDLKTMREVRRALR fusion tag) AHRAYTPNDECFFIFLDVSRDFVASGAEDRHGYIWDRHYNICLARLRHED VVNSVVFSPQEQ Theoretical MW 30962 Da including N-terminal His6ABP fusion tag Fusion Tag A purification and quantification tag (QTag) consisting of a hexahistidine sequence followed by an Albumin Binding Protein (ABP) domain derived from Streptococcal Protein G. Expression Host Escherichia coli LysA ArgA BL21(DE3) Purification IMAC purification Purity >90% as determined by Bioanalyzer Protein 230 Purity Assay Isotopic Incorporation >99% Concentration >5 μM after reconstitution in 100 μl H20 Concentration Concentration determined by LC-MS/MS using a highly pure amino acid analyzed internal Determination reference (QTag), CV ≤10%. Amount >0.5 nmol per vial, two vials supplied. Formulation Lyophilized in 100 mM Tris-HCl 5% Trehalose, pH 8.0 Instructions for Spin vial before opening. Add 100 μL ultrapure H2O to the vial. Vortex thoroughly and spin Reconstitution down. For further dilution, see Application Protocol. Shipping Shipped at ambient temperature Storage Lyophilized product shall be stored at -20°C. See COA for expiry date. Reconstituted product can be stored at -20°C for up to 4 weeks. Avoid repeated freeze-thaw cycles. Notes For research use only Product of Sweden. For research use only. -
ER-To-Golgi Trafficking and Its Implication in Neurological Diseases
cells Review ER-to-Golgi Trafficking and Its Implication in Neurological Diseases 1,2, 1,2 1,2, Bo Wang y, Katherine R. Stanford and Mondira Kundu * 1 Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA; [email protected] (B.W.); [email protected] (K.R.S.) 2 Department of Cell and Molecular Biology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA * Correspondence: [email protected]; Tel.: +1-901-595-6048 Present address: School of Life Sciences, Xiamen University, Xiamen 361102, China. y Received: 21 November 2019; Accepted: 7 February 2020; Published: 11 February 2020 Abstract: Membrane and secretory proteins are essential for almost every aspect of cellular function. These proteins are incorporated into ER-derived carriers and transported to the Golgi before being sorted for delivery to their final destination. Although ER-to-Golgi trafficking is highly conserved among eukaryotes, several layers of complexity have been added to meet the increased demands of complex cell types in metazoans. The specialized morphology of neurons and the necessity for precise spatiotemporal control over membrane and secretory protein localization and function make them particularly vulnerable to defects in trafficking. This review summarizes the general mechanisms involved in ER-to-Golgi trafficking and highlights mutations in genes affecting this process, which are associated with neurological diseases in humans. Keywords: COPII trafficking; endoplasmic reticulum; Golgi apparatus; neurological disease 1. Overview Approximately one-third of all proteins encoded by the mammalian genome are exported from the endoplasmic reticulum (ER) and transported to the Golgi apparatus, where they are sorted for delivery to their final destination in membrane compartments or secretory vesicles [1]. -
Clinical Interpretation and Implications of Whole-Genome Sequencing
Dewey, et al WGS for clinical medicine Supplemental methods Supplementary methods ....................................................................................................... 2 Genomic sequence data generation ............................................................................................ 2 Sequence alignment, genetic variant and clinical genotype identification .................. 2 Genetic variant and clinical genotype annotation ................................................................. 5 Bioinformatic prioritization of candidate inherited disease risk variants ................... 5 Manual review of candidate inherited disease risk variants ............................................. 6 Assessment of genetic risk for coronary artery disease and diabetes ........................... 8 Supplementary Tables ........................................................................................................... 9 Box. Data sources used for whole genome sequence variant annotation. .................... 9 Table S1. Summary statement definitions for inherited risk candidates. .................. 10 Table S2. Phenotypic characterization of inherited disease conditions. .................... 15 Table S3. Common single nucleotide variants used for diabetes genetic risk assessment in Caucasians. .......................................................................................................... 16 Table S4. Common single nucleotide variants used for coronary artery disease genetic risk assessment in Caucasians. -
Anti-SEC24C Antibody (ARG41212)
Product datasheet [email protected] ARG41212 Package: 100 μl anti-SEC24C antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes SEC24C Tested Reactivity Hu Tested Application WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name SEC24C Antigen Species Human Immunogen Recombinant fusion protein corresponding to aa. 915-1094 of Human SEC24C (NP_004913.2). Conjugation Un-conjugated Alternate Names SEC24-related protein C; Protein transport protein Sec24C Application Instructions Application table Application Dilution WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control HT-29 Calculated Mw 118 kDa Observed Size 118 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Gene Symbol SEC24C Gene Full Name SEC24 homolog C, COPII coat complex component Background The protein encoded by this gene is a member of the SEC24 subfamily of the SEC23/SEC24 family, which is involved in vesicle trafficking. The encoded protein has similarity to yeast Sec24p component of COPII.